KRT20, KRT5, ESR1 and ERBB2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer
Wirtz, Ralph M.
Journal of Personalized Medicine ; 11 (2021), 6. - Art.-Nr. 473. - eISSN 2075-4426
Link to original publicationhttps://dx.doi.org/10.3390/jpm11060473
InstitutionsUKU. Klinik für Urologie und Kinderurologie
Document versionpublished version (publisher's PDF)
Patients with muscle-invasive bladder cancer (MIBC) that underwent neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) show improved overall survival, especially those with pathological complete response (pCR). The response to NAC according to molecular subtypes has been discussed. Molecular targets such as estrogen receptor (ESR1) and human epidermal growth factor receptor 2 (ERBB2) play an important role in breast cancer management and have also been associated with urothelial bladder cancer. Hence, the association of Keratin 20 (KRT20) Keratin 5 (KRT5), ESR1, and ERBB2 mRNA expression in MIBC at transurethral resection (TUR-BT) with pCR after NAC was analyzed retrospectively. Formalin-fixed paraffin-embedded tumour tissue samples from TUR-BT of 54 patients (42 males, 12 females, median age of 64) with MIBC were analyzed for KRT20, KRT5, ESR1, and ERBB2 mRNA expression. After NAC, RC was performed, and the specimens were evaluated for pCR. Statistical analyses comprised nonparametric and chi2 testing, partition models, and Spearman correlation analyses. After NAC, 22 out of 54 patients (40.7%) had pCR. Tumours with an elevated expression of markers associated with luminal differentiation (KRT20, ERBB2, ESR1) were associated with a higher chance of pCR (55% vs. 15.8%, p = 0.009). Elevated ERBB2 expression was positively correlated with luminal expression features such as KRT20, and negatively with basal characteristics such as KRT5. Patients with MIBC showing a high expression of ERBB2, ESR1, or KRT20 have a significantly higher chance of pCR following NAC. These findings might improve patient selection for NAC in MIBC.
Subject headings[GND]: Blasenkrebs | Chemotherapie
[LCSH]: Bladder; Cancer | Bladder; Cancer; Adjuvant treatment
[MeSH]: Urinary bladder neoplasms; Drug therapy
[Free subject headings]: chemotherapy | muscle invasive | risk stratification | subtype
[DDC subject group]: DDC 610 / Medicine & health
LicenseCC BY 4.0 International
MetadataShow full item record
DOI & citation
Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-45707